63 related articles for article (PubMed ID: 38347460)
1. Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer.
Hou Y; Li X; Yang Y; Shi H; Wang S; Gao M
Front Immunol; 2023; 14():1274431. PubMed ID: 38022654
[TBL] [Abstract][Full Text] [Related]
2. Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.
Kobayashi T; Ito K; Kojima T; Maruyama S; Mukai S; Tsutsumi M; Miki J; Okuno T; Yoshio Y; Matsumoto H; Shimazui T; Segawa T; Karashima T; Masui K; Fukuta F; Tashiro K; Imai K; Suekane S; Nagasawa S; Higashi S; Fukui T; Ogawa O; Kitamura H; Nishiyama H
Cancer Immunol Immunother; 2022 Feb; 71(2):461-471. PubMed ID: 34235546
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of NLR and PLR for immune-related adverse events: a systematic review and meta-analysis.
Lu HR; Zhu PF; Deng YY; Chen ZL; Yang L
Clin Transl Oncol; 2024 May; 26(5):1106-1116. PubMed ID: 37682501
[TBL] [Abstract][Full Text] [Related]
4. Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-world study.
Wang Z; Bi H; Wang YD; Liu Q; Shao B; Li CQ; Fu C; Fu S; Shan GY; Chen A; Lv CC; Zeng Y
Actas Urol Esp (Engl Ed); 2024 May; 48(4):295-303. PubMed ID: 38160794
[TBL] [Abstract][Full Text] [Related]
5. Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.
Furubayashi N; Minato A; Tomoda T; Hori Y; Kiyoshima K; Negishi T; Haraguchi Y; Koga T; Harada K; Kuroiwa K; Fujimoto N; Nakamura M;
Anticancer Res; 2024 Apr; 44(4):1675-1681. PubMed ID: 38537962
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: Markers predicting immune-checkpoint inhibitor efficacy and immune-related adverse events.
Jiang QY; Xue RY
World J Gastrointest Oncol; 2024 Mar; 16(3):577-582. PubMed ID: 38577447
[TBL] [Abstract][Full Text] [Related]
7. A real-world evaluation of tislelizumab in patients with head and neck cancer.
Zheng B; Huang Z; Liu W; Zhao D; Xu X; Xiao S; Sun Y; Wang W
Transl Cancer Res; 2024 Feb; 13(2):808-818. PubMed ID: 38482433
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors.
Mokbel S; Baciarello G; Lavaud P; Omlin A; Calabrò F; Cathomas R; Aeppli S; Parent P; Giannatempo P; Koster KL; Appel N; Gonnet P; Angius G; Tsantoulis P; Arkenau HT; Cattrini C; Messina C; Zeghondy J; Morelli C; Loriot Y; Formica V; Patrikidou A
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672547
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature.
Deng Y; Huang M; Deng R; Wang J
Medicine (Baltimore); 2024 Mar; 103(12):e37562. PubMed ID: 38518047
[TBL] [Abstract][Full Text] [Related]
10. Change in the neutrophil-lymphocyte ratio may predict early recurrence in operated bladder cancer.
Çolak R; Erdem GU; Kapar C; Gültürk İ; Aksu F; Erdal GŞ; Yılmaz M; Tural D
Asia Pac J Clin Oncol; 2024 Apr; ():. PubMed ID: 38572819
[TBL] [Abstract][Full Text] [Related]
11. Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.
Mellgard G; Patel VG; Zhong X; Joshi H; Qin Q; Wang B; Parikh A; Jun T; Alerasool P; Garcia P; Gogerly-Moragoda M; Leiter A; Gallagher EJ; Oh WK; Galsky MD; Tsao CK
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2833-2841. PubMed ID: 35788726
[TBL] [Abstract][Full Text] [Related]
12. CT-derived skeletal muscle change before immunotherapy predicts survival of advanced gastric cancer: associations with inflammatory markers and liver lipid metabolism.
Hayano K; Ohira G; Matsumoto Y; Kurata Y; Otsuka R; Hirata A; Toyozumi T; Murakami K; Uesato M; Matsubara H
Int J Clin Oncol; 2024 May; ():. PubMed ID: 38775896
[TBL] [Abstract][Full Text] [Related]
13. Associations between "Cancer Risk", "Inflammation" and "Metabolic Syndrome": A Scoping Review.
Vitale E; Rizzo A; Santa K; Jirillo E
Biology (Basel); 2024 May; 13(5):. PubMed ID: 38785834
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.
Yang M; Zhang J; Wei D; Yu T; Chen Z; Liu X; Zhu H
BMC Cancer; 2024 Feb; 24(1):196. PubMed ID: 38347460
[TBL] [Abstract][Full Text] [Related]
15. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of preoperative lymphocyte-related systemic inflammatory biomarkers in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: a systematic review and meta-analysis.
Shao Y; Li W; Wang D; Wu B
World J Surg Oncol; 2020 Oct; 18(1):273. PubMed ID: 33097052
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the clinical value of hematological parameters in patients with urothelial carcinoma of the bladder.
Luo Y; Shi X; Li W; Mo L; Yang Z; Li X; Qin L; Mo W
Medicine (Baltimore); 2018 Apr; 97(14):e0351. PubMed ID: 29620666
[TBL] [Abstract][Full Text] [Related]
18. Adrenal crisis mainly manifested as recurrent syncope secondary to tislelizumab: a case report and literature review.
Wei H; Zuo A; Chen J; Zheng C; Li T; Yu H; Guo Y
Front Immunol; 2023; 14():1295310. PubMed ID: 38292481
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
